Title: Recent and anticipated novel drug approvals (1Q 2025 through 4Q 2025).
Authors: Matthew H. Rim, Brittany L Karas, Farah Barada, Mary Golf, Vishal Prakash et al. (and 1 more)
Year: 2025
Paper ID: 6358cf23d179be1e185307adafab3c584fabe0ad
URL: https://www.semanticscholar.org/paper/6358cf23d179be1e185307adafab3c584fabe0ad
Venue: American Journal of Health-System Pharmacy

Abstract:
DISCLAIMER
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.


PURPOSE
Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.


SUMMARY
Selected drug approvals anticipated in the 12-month period covering each quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 60 novel drugs awaiting US Food and Drug Administration approval. This year's pipeline features gene and cell therapies for rare diseases, agents for neurological disorders, and several novel treatments for cancers and various disease states.


CONCLUSION
Novel therapies continue to strengthen the current drug pipeline.
